TSP, a Syneos Health company

TSP is heading to Boston in just a couple of weeks for LEAP HR Life Science - East! Are you attending? Connect with Jackie Tisch, Mike Gamble, and Chris Passmore, M.Ed. We look forward to seeing you there! #LEAPHREast #LifeSciences To learn more about the LEAP HR East here: https://lnkd.in/gieKEbJc

We are thrilled to announce the release of the latest edition of POPsights Magazine, packed with thought leadership pieces and exclusive features from TSP’s experts. This issue delves deep into the dynamics of life sciences talent acquisition, providing you with actionable insights and innovative strategies. Hear from Angie Aldinger, Mike Gamble, Mike Moran, Maya Yankelevich Garza, PhD, Matthew Hart, Stefan Werdegar, and Abby Kripke. Download our full magazine here: https://lnkd.in/eUDh6aHb

After a busy first half of 2024, several companies are expecting key data readouts in the neuropsychiatric and neurodegenerative disease spaces during the next six months. Check out these 5 neuro data readouts to watch for the remainder of the year!

At TSP, we are all about getting curious, and we're excited to hear from you! In the dynamic world of life sciences, retaining top talent is crucial for success. We're curious to learn more about what strategies you find most effective in keeping your employees engaged and motivated. Take a moment to share your insights and see how your peers are tackling this challenge. #employeeretention

TSP’s newest edition of the POPsights Labor Market Report is out now! Dive deep into: - Key Labor Market Trends: Job availability, candidate behavior, and employer branding. - Economic Impacts: How inflation, investment, and interest rates shape the market. - Technological Integration: AI's role in recruitment and engagement. - Salary Trends: Current compensation insights and regional variations. - Future Outlook: Growth areas and emerging trends. Empower your strategies with the latest data and insights. Download our full report here: https://lnkd.in/eetZKvXY

Recruiting might seem straightforward, but there's a lot more to it than meets the eye. Our VP of Client Solutions, Angie Aldinger, dives deep into the misconceptions and realities of the recruiting world in her latest blog post, "Everyone Thinks They’re a Recruiter." Check it out here: https://lnkd.in/emc4wBfr

We're all about results and relationships. Hear directly from our clients about the impact we've made together. 🌟 #ClientTestimonials #SuccessTogether

Happy Rebrandiversary! This month, we are thrilled to mark the one-year anniversary of our bigger, better brand that perfectly captures our expertise and leadership in the life sciences talent solutions industry. After several decades, we made the strategic choice last year to bring a new logo, look and voice to TSP’s talent solutions, and we’ve made tremendous strides in every aspect: -      Continuous improvement and innovation -      Introducing new and enhanced solutions -      Added new locations around the globe to support additional customers -      A fresh and modern brand that resonates visually and emotionally The positive feedback from our customers has been incredible, and we are proud of the thoughtful, finely-tuned solutions we deliver to meet their unique needs. Thank you to everyone who has been a part of this journey with us! Here's to many more years of growth and success together. #TSPAnniversary #LifeSciences #PowerofPersonal #HappyRebrandiversary

🏳️🌈Here at Syneos Health, we come together to celebrate and support our LGBTQIA+ community and allies. PRIDE Month is more than just a time to honor the diverse identities and experiences within the LGBTQIA+ spectrum; it is an opportunity for us to stand in solidarity, to educate, and to advocate for equality and inclusion. We asked our employees what PRIDE means to them and here’s what they had to say. #SyneosHealth #StandProudStandTogether

"The emergence of AstraZeneca as a popular pick for cancer patient groups follows years of fast growth. In 2017, AstraZeneca reported (PDF) $4 billion in oncology revenue. Since then, the company’s annual cancer sales growth rate has ranged from 13% to 50%, culminating in oncology revenues topping (PDF) $17 billion last year. Four of AstraZeneca’s cancer drugs brought in $2.5 billion or more in 2023."